Core Insights - The medical services sector experienced a rise of 1.53% on October 21, with He Yuan Biological leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Medical Services Sector Performance - He Yuan Biological (688238) closed at 7.78, with an increase of 8.21% and a trading volume of 282,000 shares, amounting to 217 million yuan [1] - Other notable performers included Bei Rui Gene (000710) with a closing price of 13.22, up 3.77%, and Yao Kang Biological (688046) at 16.71, up 3.66% [1] - The sector saw a total net inflow of 250 million yuan from main funds, while retail investors experienced a net outflow of approximately 74 million yuan [2] Fund Flow Analysis - Major net inflows were observed in companies like Yao Ming Kang De (603259) with 353 million yuan, while retail investors showed significant outflows [3] - The top three companies by main fund inflow were Yao Ming Kang De (603259), Kang Long Hua Cheng (300759), and Hao Yuan Medical (688131) [3] - Retail investors showed a negative trend in several companies, indicating a cautious sentiment in the market [3]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-052 成都市贝瑞和康基因技术股份有限公司 关于控股股东之一致行动人所持公司股份被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖标的物为成都市贝瑞和康基因技术股份有限公司（以下简称 "贝瑞基因"或"公司"）控股股东之一致行动人侯颖女士持有的本公司 400,000 股股票，占其持有公司股份的比例为 100.00%，占公司总股本的比例 为 0.11%。上述被司法拍卖的股份为无限售流通股，已被全部质押和司法再冻 结。 2、在本次拍卖事项中，所涉 400,000 股股份为第二次司法拍卖，最终流 拍。流拍股份将依据成渝金融法院后续裁定进行处置，公司将持续关注后续 进展并根据相关法律法规的规定履行信息披露义务。 3、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大 影响。 一、本次司法拍卖的基本情况 | 股 | 是否为控 | 拍 | 本次被司 | 占其所 | 占公司 | 是否 | 东 | 股股东及 | 拍卖 | 卖 | | | | --- | --- ...

Core Viewpoint - Berry Genomics (000710) has announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its α and β thalassemia gene testing kit, marking a significant milestone in the clinical application of third-generation sequencing technology [1] Group 1 - The gene testing kit utilizes single-molecule sequencing technology for the qualitative detection of thalassemia gene mutations in human peripheral venous whole blood samples [1] - The certification of the testing kit represents a critical breakthrough in both technology and strategy for Berry Genomics, facilitating the clinical transformation of its third-generation sequencing technology [1]

Core Insights - Berry Genomics (000710.SZ) announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its α and β-thalassemia gene testing kit using single-molecule sequencing technology, marking a significant milestone in the clinical application of third-generation sequencing technology [1] Group 1 - The testing kit represents a critical breakthrough in technology and strategy for Berry Genomics, facilitating the transition from gene testing services to a high-value model that integrates "equipment + reagents + intelligent analysis" [1] - The kit utilizes CATSA technology and single-molecule real-time (SMRT) high accuracy (HiFi) mode to achieve "one-step" detection of all mutation types of α and β-thalassemia, addressing traditional testing limitations and detection gaps [1] - The AI data analysis platform, validated by 300,000 samples, completes the "testing technology - data processing - clinical report" closed loop, enhancing the overall efficiency and reliability of the testing process [1] Group 2 - The successful registration of the testing kit strengthens the systematic layout of "research - hardware - products," accelerating the company's strategic upgrade and laying a solid product foundation for establishing a "Chinese solution" for third-generation sequencing [1]

Core Viewpoint - Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its α and β thalassemia gene testing kit, marking a significant breakthrough in the clinical application of third-generation sequencing technology [1] Group 1 - The gene testing kit utilizes single-molecule sequencing to qualitatively detect mutations in thalassemia genes from human peripheral venous whole blood samples [1] - The kit specifically identifies four deletions and three point mutations in the α-globin gene, as well as sixteen point mutations in the β-globin gene [1] - The acquisition of the registration certificate enhances the systematic layout of the company's "research - hardware - product" strategy, laying a product foundation for establishing a "Chinese solution" for third-generation sequencing [1]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-051 成都市贝瑞和康基因技术股份有限公司 关于全资子公司基于三代基因测序技术的检测试剂盒 获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或"贝瑞基因"） 全资子公司杭州贝瑞和康基因诊断技术有限公司的α和β地中海贫血基因检测 试剂盒(单分子测序法)于近日正式获得国家药品监督管理局（NMPA）颁发的医疗 器械注册证（体外诊断试剂）（注册证编号：国械注准20253402000）。现将具 体情况公告如下： | 产品名称 | α和β地中海贫血基因检测试剂盒(单分子测序法) | | --- | --- | | 注册人名称 | 杭州贝瑞和康基因诊断技术有限公司 | | 注册证编号 | 国械注准20253402000 | | 证书类型 | 第三类医疗器械注册证 | | 包装规格 | 建库试剂：产品编号R1010，规格：96人份/盒。 | | | 测序试剂：产品编号R4001，规格：1次反应/测试，1测试/盒。 | | 有效期 | 2 ...

Core Insights - The Chinese gene editing industry is experiencing rapid growth, with a projected market size of approximately 2.741 billion yuan in 2024, representing a year-on-year increase of 33.19% [1][8] - Gene editing technology has broad application prospects in both medical and agricultural fields, including the treatment of genetic diseases and the cultivation of high-yield, disease-resistant crops [1][8] Industry Overview - Gene editing is a technology that allows precise modifications to the genome of organisms, utilizing tools such as CRISPR-Cas systems and specific nucleases [2][6] - The technology has evolved through various methods, including ZFNs, TALENs, and CRISPR, and is widely applied in genetic disease treatment, agricultural breeding, and cancer therapy [2][6] Industry Development History - The Chinese gene editing industry began in the 1970s, with significant milestones including the emergence of transgenic crops in the 1990s and the rise of CRISPR-Cas9 technology in the 2010s [6][7] - The industry entered a period of rapid commercialization starting in 2021, with the first gene editing therapies entering clinical trials and significant advancements in agricultural applications [7] Industry Value Chain - The upstream of the gene editing industry includes tools and patent technologies, raw materials, and laboratory equipment, while the midstream focuses on product development and technical services [8] - The downstream applications span medical, agricultural, and industrial sectors, highlighting the diverse utility of gene editing technologies [8] Market Size - The market size of the Chinese gene editing industry is expected to reach approximately 2.741 billion yuan in 2024, with a growth rate of 33.19% year-on-year [1][9] Key Companies' Performance - Major players in the industry include BGI Genomics, Berry Genomics, and others, focusing on CRISPR-Cas9 therapies for genetic diseases and expanding into cancer and neurological disease treatments [10] - Shanghai BGI has achieved significant breakthroughs in treating β-thalassemia, while Guangzhou Ruifeng has developed gene editing drugs that have shown high efficacy in clinical trials [10][11] Industry Development Trends 1. Continuous technological innovation is driving breakthroughs in precision medicine, with advancements in CRISPR technology and AI integration enhancing editing efficiency and accuracy [12] 2. The application of gene editing is expanding across various fields, including agriculture and industrial applications, with significant improvements in crop yields and production processes [13][14] 3. Strong policy support and capital investment are fostering a robust industry ecosystem, with the Chinese government prioritizing gene editing in its biotechnological development plans [15]

Core Insights - The Chinese epigenetics industry has made significant progress in recent years, becoming a research hotspot in the life sciences field, with a market size projected to reach approximately 4.396 billion yuan in 2024, reflecting a year-on-year growth of 62.27% [1][8][10] - The growth is driven by advancements in technologies such as high-throughput sequencing and single-cell sequencing, leading to broader applications in disease diagnosis, treatment, basic research, and crop breeding [1][8][10] Industry Overview - Epigenetics studies heritable changes in gene expression that do not involve changes to the underlying DNA sequence, focusing on the regulation of genes at the transcriptional level [2][4] - Key epigenetic modifications include DNA methylation, histone modification, chromatin remodeling, and RNA modifications [2][4] Industry Development History - The exploration phase of epigenetics in China occurred from the 1940s to 1970s, with significant setbacks due to political influences [4][5] - The initial development phase from the 1980s to 1990s saw the introduction of international genetic theories and the beginning of research into DNA methylation and histone modifications [5][6] - From 2000 to 2010, rapid development occurred, with China participating in the Human Epigenome Project and launching significant research initiatives [6][8] - Since 2010, the industry has matured, with increased international collaboration and applications in disease mechanisms, agriculture, and environmental adaptation [6][8] Industry Value Chain - The upstream of the epigenetics industry includes raw materials such as biological reagents and nucleic acid extraction kits, as well as scientific equipment like high-throughput sequencers and bioinformatics software [7] - The midstream focuses on research and development, while the downstream applications span medical fields (e.g., cancer early screening and precision treatment) and agriculture [7] Market Size - The Chinese epigenetics market is expected to reach approximately 4.396 billion yuan in 2024, with a year-on-year growth of 62.27%, driven by technological advancements and increasing market demand [1][8][10] Industry Trends - Technological innovation and multi-omics integration are driving advancements in precision medicine, with AI and single-cell sequencing enhancing early cancer screening capabilities [12][13] - Applications of epigenetics are expanding into agriculture, environmental science, and health management, demonstrating versatility across various fields [13] - Policy support and market expansion are fostering a comprehensive innovation ecosystem, with increased gene testing coverage and collaboration in international research initiatives [14]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-050 特别提示： 1、本次拍卖标的物为成都市贝瑞和康基因技术股份有限公司（以下简称 "贝瑞基因"或"公司"）控股股东之一致行动人侯颖女士持有的本公司 400,000 股股票，占其持有公司股份的比例为 100.00%，占公司总股本的比例 为 0.11%。上述将被司法拍卖的股份为无限售流通股，已被全部质押和司法再 冻结。 成都市贝瑞和康基因技术股份有限公司 2、本次拍卖事项所涉及的股份，为公司于 2025 年 9 月 16 日披露的《关 于控股股东之一致行动人所持公司股份被司法拍卖的进展公告》（公告编号： 2025-049）所述侯颖女士持有的公司400,000股股份于2025年9月12日10:00 时结束后，因在规定时间内无人出价流拍的股份。本次拍卖是侯颖女士持有 的 400,000 股股份的二次拍卖。 关于控股股东之一致行动人所持公司股份将被司法拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 4、公司目前生产经营情况正常，该事项未对公司正常经营活动产生重大 影响。 公司于近日收到控 ...

Core Points - Chengdu Beirui Hekang Gene Technology Co., Ltd. announced that the judicial auction of 400,000 shares held by its controlling shareholder's concerted actor, Hou Ying, ended on September 12, 2025, with no bids placed, resulting in a failed auction [1] - The shares in question represent 100.00% of Hou Ying's holdings and 0.11% of the company's total share capital, and are unrestricted circulating shares that have been fully pledged and judicially frozen [1] - As of the announcement date, Hou Ying has cumulatively had 19,805,661 shares auctioned judicially, but the company's production and operations remain normal, and the failed auction has not caused significant adverse effects [1] - The shares that failed to auction will be disposed of according to the ruling of the Chengyu Financial Court, and the company will continue to disclose updates on this matter [1]